Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MPS4
MCID: MCP004
MIFTS: 57

Mucopolysaccharidosis Iv (MPS4)

Categories: Bone diseases, Eye diseases, Fetal diseases, Genetic diseases, Liver diseases, Metabolic diseases, Neuronal diseases, Rare diseases, Respiratory diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Mucopolysaccharidosis Iv

About this section

MalaCards integrated aliases for Mucopolysaccharidosis Iv:

Name: Mucopolysaccharidosis Iv 38 12 44 15 73
Mucopolysaccharidosis, Mps-Iv-a 12 29 6 73
Mucopolysaccharidosis Type Iv 53 25 59 37
Mucopolysaccharidosis Type Iva 12 24 53
Mucopolysaccharidosis Type 4 76 53 59
Morquio a Disease 12 24 53
Morquio Disease 53 25 59
Galactosamine-6-Sulfatase Deficiency 12 53
Mucopolysaccharidosis Type Ivb 12 73
Morquio Syndrome a 12 53
Galns Deficiency 53 73
Mps Iva 24 53
Mpsiv 53 59
Mps4 53 59
N-Acetylgalactosamine-6-Sulfate Sulfatase Deficiency 53
Deficiency of N-Acetylgalactosamine-6-Sulphatase 12
Deficiency of Chondroitinsulphatase 12
Mucopolysaccharidosis, Mps-Iv 12
Mucopolysaccharidosis Type 4a 53
Mps Iv - Morquio Syndrome a 12
Mps Iv - Morquio Syndrome B 12
Morquio-Brailsford Disease 25
Mucopolysaccharidosis Iv 25
Morquio Syndrome Type a 24
Morquio Disease Type a 53
Chondroosteodystrophy 12
Osteochondrodystrophy 12
Morquio's Syndrome 25
Morquio's Disease 25
Morquios Syndrome 55
Morquio Syndrome 25
Mps Iv a 55
Mps 4a 53
Mpsiva 53
Mps Iv 25
Mps4a 53

Characteristics:

Orphanet epidemiological data:

59
mucopolysaccharidosis type 4
Inheritance: Autosomal recessive; Prevalence: <1/1000000 (Sweden),1-9/100000 (Sweden),1-9/1000000 (Norway),1-5/10000 (Norway),1-9/1000000 (Denmark),1-5/10000 (Denmark),1-9/1000000 (Germany),1-9/100000 (Ireland),1-9/1000000 (Czech Republic),1-9/1000000 (Canada),1-9/1000000 (Tunisia),1-9/1000000 (Taiwan, Province of China),1-9/1000000 (Netherlands),1-9/1000000 (Poland); Age of onset: Childhood;

Classifications:

MalaCards categories:
Global: Rare diseases Metabolic diseases Fetal diseases Genetic diseases
Anatomical: Eye diseases Bone diseases Neuronal diseases Skin diseases Respiratory diseases Liver diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare eye diseases
Rare bone diseases
Inborn errors of metabolism
Developmental anomalies during embryogenesis


Sources

Summaries for Mucopolysaccharidosis Iv

About this section
NIH Rare Diseases : 53 Mucopolysaccharidosis type IV (MPS IV), also known as Morquio syndrome, is a rare metabolic condition in which the body is unable to break down long chains of sugar molecules called glycosaminoglycans. As a result, toxic levels of these sugars accumulate in cell structures called lysosomes, leading to the various signs and symptoms associated with the condition. Affected people generally develop features of MPS IV between the ages of 1 and 3. These signs and symptoms may include abnormalities of the skeleton, eyes, heart and respiratory system. There are two forms of MPS IV: MPS IVA is caused by changes (mutations) in the GALNS gene. MPS IVB is caused by mutations in the GLB1 gene. Both forms are inherited in an autosomal recessive manner. Treatment is based on the signs and symptoms present in each person.

MalaCards based summary : Mucopolysaccharidosis Iv, also known as mucopolysaccharidosis, mps-iv-a, is related to morquio syndrome and mucopolysaccharidosis, type iva, and has symptoms including ulnar deviation of the wrist An important gene associated with Mucopolysaccharidosis Iv is GALNS (Galactosamine (N-Acetyl)-6-Sulfatase), and among its related pathways/superpathways are Glycosaminoglycan degradation and Lysosome. The drugs Alendronate and Teriparatide have been mentioned in the context of this disorder. Affiliated tissues include bone, heart and skin, and related phenotypes are macrocephaly and short neck

Disease Ontology : 12 A mucopolysaccharidosis characterized by a deficiency of the lysosomal enzymes galactose 6-sulfate sulfatase (Type A) or beta-galactosidase (Type B) needed to break down the keratan sulfate sugar chain.

Genetics Home Reference : 25 Mucopolysaccharidosis type IV (MPS IV), also known as Morquio syndrome, is a progressive condition that mainly affects the skeleton. The rate at which symptoms worsen varies among affected individuals.

Wikipedia : 76 Mucopolysaccharidoses are a group of metabolic disorders caused by the absence or malfunctioning of... more...

GeneReviews: NBK148668
Sources

Related Diseases for Mucopolysaccharidosis Iv

About this section

Diseases in the Mucopolysaccharidosis-Plus Syndrome family:

Mucopolysaccharidosis, Type Iiia Mucopolysaccharidosis, Type Iiib
Mucopolysaccharidosis, Type Iiic Mucopolysaccharidosis, Type Iiid
Mucopolysaccharidosis, Type Iva Mucopolysaccharidosis, Type Ivb
Mucopolysaccharidosis, Type Vi Mucopolysaccharidosis, Type Vii
Mucopolysaccharidosis, Type Ii Mucopolysaccharidosis, Type Ix
Mucopolysaccharidosis Iii Mucopolysaccharidosis Iv
Mucopolysaccharidosis Type 2, Severe Form

Diseases related to Mucopolysaccharidosis Iv via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 46)
# Related Disease Score Top Affiliating Genes
1 morquio syndrome 32.7 APRT GALNS GLB1
2 mucopolysaccharidosis, type iva 31.8 ARSH GALNS
3 mucopolysaccharidosis-plus syndrome 29.8 APRT ARSH GALNS
4 lysosomal storage disease 29.4 CTSA GALNS GLB1 NEU1
5 gangliosidosis gm1 29.3 CTSA GALNS GLB1 NEU1
6 osteochondrodysplasia 11.6
7 dyggve-melchior-clausen disease 11.4
8 spondyloepiphyseal dysplasia, maroteaux type 11.3
9 morquio syndrome c 11.3
10 spondyloepiphyseal dysplasia with congenital joint dislocations 11.2
11 mucopolysaccharidosis, type ivb 11.2
12 dermochondrocorneal dystrophy of françois 11.1
13 pectus carinatum 11.0
14 brachyolmia 11.0
15 obsessive-compulsive disorder 10.3
16 spinal cord injury 10.1
17 hypophosphatasia 10.1
18 mucopolysaccharidosis, type ii 10.0 ARSH GALNS
19 mucopolysaccharidosis, type vii 10.0 GALNS GLB1
20 mucopolysaccharidosis, type vi 10.0 ARSH GALNS
21 inclusion-cell disease 10.0 CTSA GLB1
22 gangliosidosis gm2 10.0 CTSA GLB1
23 hydrops fetalis, nonimmune, and/or atrial septal defect 9.9
24 fetal edema 9.9
25 hydrops fetalis 9.9
26 mucolipidosis ii alpha/beta 9.9 ARSH NEU1
27 adenine phosphoribosyltransferase deficiency 9.9 APRT GALNS
28 legg-calve-perthes disease 9.9
29 dwarfism 9.9
30 tyrosinemia, type iii 9.9
31 tracheomalacia 9.9
32 respiratory failure 9.9
33 ehlers-danlos syndrome 9.9
34 mitral valve disease 9.9
35 tyrosinemia 9.9
36 spinal cord infarction 9.9
37 sphingolipidosis 9.9 CTSA GLB1
38 developmental dysplasia of the hip 1 9.8
39 mucopolysaccharidoses 9.8
40 mucolipidosis iv 9.8 CTSA GALNS GLB1
41 scheie syndrome 9.8 CTSA GALNS GLB1
42 multiple sulfatase deficiency 9.8 ARSH GALNS
43 neuraminidase deficiency 9.8 CTSA GLB1 NEU1
44 glycoproteinosis 9.8 CTSA GLB1 NEU1
45 galactosialidosis 9.8 CTSA GLB1 NEU1
46 tay-sachs disease 9.8 CTSA GLB1 NEU1

Graphical network of the top 20 diseases related to Mucopolysaccharidosis Iv:



Diseases related to Mucopolysaccharidosis Iv
Sources

Symptoms & Phenotypes for Mucopolysaccharidosis Iv

About this section

Human phenotypes related to Mucopolysaccharidosis Iv:

59 32 (show all 35)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 macrocephaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0000256
2 short neck 59 32 hallmark (90%) Very frequent (99-80%) HP:0000470
3 joint dislocation 59 32 frequent (33%) Frequent (79-30%) HP:0001373
4 genu valgum 59 32 hallmark (90%) Very frequent (99-80%) HP:0002857
5 abnormality of epiphysis morphology 59 32 hallmark (90%) Very frequent (99-80%) HP:0005930
6 gait disturbance 59 32 hallmark (90%) Very frequent (99-80%) HP:0001288
7 scoliosis 59 32 frequent (33%) Frequent (79-30%) HP:0002650
8 kyphosis 59 32 frequent (33%) Frequent (79-30%) HP:0002808
9 hyperlordosis 59 32 frequent (33%) Frequent (79-30%) HP:0003307
10 coarse facial features 59 32 frequent (33%) Frequent (79-30%) HP:0000280
11 hearing impairment 59 32 hallmark (90%) Very frequent (99-80%) HP:0000365
12 delayed skeletal maturation 59 32 hallmark (90%) Very frequent (99-80%) HP:0002750
13 corneal opacity 59 32 hallmark (90%) Very frequent (99-80%) HP:0007957
14 carious teeth 59 32 frequent (33%) Frequent (79-30%) HP:0000670
15 pectus carinatum 59 32 hallmark (90%) Very frequent (99-80%) HP:0000768
16 anteverted nares 59 32 frequent (33%) Frequent (79-30%) HP:0000463
17 short stature 59 32 hallmark (90%) Very frequent (99-80%) HP:0004322
18 mucopolysacchariduria 59 32 hallmark (90%) Very frequent (99-80%) HP:0008155
19 cognitive impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0100543
20 abnormality of the metaphysis 59 32 hallmark (90%) Very frequent (99-80%) HP:0000944
21 hernia 59 32 frequent (33%) Frequent (79-30%) HP:0100790
22 platyspondyly 59 32 frequent (33%) Frequent (79-30%) HP:0000926
23 coxa valga 59 32 frequent (33%) Frequent (79-30%) HP:0002673
24 joint hyperflexibility 59 32 hallmark (90%) Very frequent (99-80%) HP:0005692
25 short thorax 59 32 hallmark (90%) Very frequent (99-80%) HP:0010306
26 reduced bone mineral density 59 32 hallmark (90%) Very frequent (99-80%) HP:0004349
27 wide mouth 59 32 frequent (33%) Frequent (79-30%) HP:0000154
28 abnormality of the ribs 59 32 hallmark (90%) Very frequent (99-80%) HP:0000772
29 spinal canal stenosis 59 32 frequent (33%) Frequent (79-30%) HP:0003416
30 grayish enamel 59 32 frequent (33%) Frequent (79-30%) HP:0000683
31 bowing of the long bones 59 Very frequent (99-80%)
32 abnormality of the dentition 59 Very frequent (99-80%)
33 abnormality of the heart valves 59 Frequent (79-30%)
34 abnormality of dental enamel 59 Frequent (79-30%)
35 abnormal heart valve morphology 32 frequent (33%) HP:0001654

UMLS symptoms related to Mucopolysaccharidosis Iv:


ulnar deviation of the wrist

MGI Mouse Phenotypes related to Mucopolysaccharidosis Iv:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.02 APRT CTSA GALNS GLB1 NEU1
Sources

Drugs & Therapeutics for Mucopolysaccharidosis Iv

About this section

Drugs for Mucopolysaccharidosis Iv (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alendronate Approved Phase 4,Phase 2 66376-36-1, 121268-17-5 2088
2
Teriparatide Approved, Investigational Phase 4,Phase 2 52232-67-4 16133850
3
Pamidronate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 40391-99-9 4674
4
Methyclothiazide Approved Phase 4 135-07-9 4121
5
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 1406-16-2
6
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
7
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
8 Bone Density Conservation Agents Phase 4,Phase 2,Phase 3,Phase 1
9 Diphosphonates Phase 4,Phase 2,Phase 3,Phase 1
10 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
11 Micronutrients Phase 4,Phase 3
12 Calciferol Phase 4,Phase 2
13 Ergocalciferols Phase 4
14 Vitamin D2 Phase 4
15 Trace Elements Phase 4,Phase 3
16 Vitamins Phase 4,Phase 3,Phase 2
17 Gentamicins Phase 4
18 Anti-Bacterial Agents Phase 4
19 Natriuretic Agents Phase 4,Phase 3,Phase 2
20 diuretics Phase 4
21 Sodium Chloride Symporter Inhibitors Phase 4
22 Vaccines Phase 4
23
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
24
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 55-98-1 2478
25
Fludarabine Approved Phase 2, Phase 3,Phase 3,Not Applicable 75607-67-9, 21679-14-1 30751
26
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
27
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
28
Methotrexate Approved Phase 2, Phase 3 59-05-2, 1959-05-2 126941
29
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 3 216503-57-0
30
Vidarabine Approved, Investigational Phase 2, Phase 3,Phase 3 24356-66-9 32326 21704
31
Etidronic acid Approved Phase 2, Phase 3,Phase 3 7414-83-7, 2809-21-4 3305
32
Zoledronic acid Approved Phase 3,Phase 2 118072-93-8 68740
33
Denosumab Approved Phase 3,Phase 2 615258-40-7
34
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
35
Calcitriol Approved, Nutraceutical Phase 3 32222-06-3 5280453 134070
36 Cyclosporins Phase 2, Phase 3,Phase 1,Not Applicable
37 Antifungal Agents Phase 2, Phase 3,Phase 1
38 Dermatologic Agents Phase 2, Phase 3,Phase 1
39 Antilymphocyte Serum Phase 2, Phase 3
40 Antirheumatic Agents Phase 2, Phase 3,Phase 3,Phase 1
41 Folic Acid Antagonists Phase 2, Phase 3
42 Calcineurin Inhibitors Phase 2, Phase 3,Phase 1
43 Thymoglobulin Phase 2, Phase 3
44 Folate Phase 2, Phase 3
45 Vitamin B9 Phase 2, Phase 3
46 Alkylating Agents Phase 2, Phase 3,Phase 3,Phase 1
47 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 3
48 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
49 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3
50 Vitamin B Complex Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 154)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta Completed NCT02303873 Phase 4 Alendronate
2 Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta Completed NCT01713231 Phase 4
3 Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta Completed NCT00131469 Phase 4 Teriparatide (FORTEO)
4 Bisphosphonate Therapy for Osteogenesis Imperfecta Completed NCT00159419 Phase 4 Alendronate;Pamidronate
5 A Study to Assess the Long-term Performance of SmartSet® HV and SmartSet® GHV Bone Cements in Primary Total Hip Replacement Completed NCT00872066 Phase 4
6 A Randomised Single Centre Study to Compare the Long-term Wear Characteristics of Marathonâ„¢ and Enduronâ„¢ Polyethylene Cup Liners in Primary Total Hip Replacement Completed NCT00208442 Phase 4
7 Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid Recruiting NCT03735537 Phase 4 Teriparatide Pen Injector;Zoledronic Acid
8 Immunodeficiency in Cartilage-hair Hypoplasia: Sub-project on Safety of Vaccination Against Chickenpox Enrolling by invitation NCT02383797 Phase 4
9 Morquio's Syndrome: a Case Study Terminated NCT00609440 Phase 4
10 A Randomised Study to Compare Metal Ion Release and Long-term Performance of the Pinnacleâ„¢ Cup With a Ceramic-on-Metal or a Metal-on-Metal Bearing Terminated NCT00873444 Phase 4
11 A Single Centre Study to Assess the Long-term Performance of the DePuy ASRâ„¢ System in Primary Hip Resurfacing Surgery Terminated NCT00872794 Phase 4
12 A Two Centre Study to Assess the Stability and Long-term Performance of the C-Stemâ„¢ AMT in a Total Primary Hip Replacement Terminated NCT00872573 Phase 4
13 Multi-Centre Study to Assess the Long-term Performance of the DePuy ASRâ„¢ System in Resurfacing and Primary Total Hip Replacement Terminated NCT00872547 Phase 4
14 A Single Centre Study to Assess the Long-term Performance of the Pinnacleâ„¢ Cup With a Ceramic-on-ceramic Bearing in Primary Total Hip Replacement Terminated NCT00872222 Phase 4
15 A Multi-centre Study to Assess the Long-term Performance of the Summitâ„¢ Hip in Primary Total Hip Replacement Terminated NCT00208390 Phase 4
16 A Multi-centre Study to Assess the Long-term Performance of the DePuy ASRâ„¢ System in Primary Hip Resurfacing Surgery Terminated NCT00208377 Phase 4
17 A Two Centre Study to Assess the Long-term Performance of the Pinnacleâ„¢ Cup With a Metal-on-Metal Bearing in Primary Total Hip Replacement Terminated NCT00208364 Phase 4
18 A Multi-centre Study to Assess the Long-term Performance of the Pinnacleâ„¢ Cup With a Polyethylene-on-metal Bearing in Primary Total Hip Replacement Withdrawn NCT00208429 Phase 4
19 BMN 110 Phase 3B in Australian Patients Unknown status NCT01966029 Phase 3 BMN 110
20 Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis Unknown status NCT01087398 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen);Cyclosporin, Methotrexate (GVHD prophylaxis)
21 Allogeneic Transplantation For Severe Osteopetrosis Unknown status NCT00775931 Phase 2, Phase 3 Campath-1H;Cyclophosphamide;Busulfan;Fludarabine monophosphate
22 Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone Unknown status NCT00445575 Phase 2, Phase 3 risedronate;placebo;risedronate;placebo
23 Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases Unknown status NCT01019876 Phase 2, Phase 3 Fludarabine;Cyclophosphamide;Cyclophosphamide 40;Cyclophosphamide 30
24 Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Completed NCT01415427 Phase 3 BMN 110 - Weekly;BMN 110 - Every Other Week
25 A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Completed NCT01275066 Phase 3 BMN 110 Weekly;Placebo;BMN 110 Every Other Week
26 Phase III Randomized Study of Interferon Gamma in Children With Severe, Congenital Osteopetrosis Completed NCT00004402 Phase 3 calcitriol;interferon gamma
27 An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta Completed NCT00982124 Phase 3 Zoledronic Acid
28 Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children Completed NCT00106028 Phase 3 risedronate sodium (Actonel);Placebo
29 Pamidronate to Treat Osteogenesis Imperfecta in Children Completed NCT00005901 Phase 3 Pamidronate (Aredia)
30 Growth Hormone Therapy in Osteogenesis Imperfecta Completed NCT00001305 Phase 3 Humatrope;Nutropin;GRH
31 A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome Completed NCT00017927 Phase 3 Pegvisomant
32 Open-label Extension Denosumab Study in Children and Young Adults With Osteogenesis Imperfecta Recruiting NCT03638128 Phase 3 Denosumab
33 Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI Recruiting NCT02352753 Phase 3 Denosumab
34 A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia Active, not recruiting NCT03197766 Phase 3 BMN 111;Placebo
35 An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia Enrolling by invitation NCT03424018 Phase 3 BMN 111
36 A Randomised Multi-centre Study to Compare the Long-term Performance of the Future Hip to 3 Other Implants in Primary Total Hip Replacement Terminated NCT00208468 Phase 3
37 A Randomised Single Centre Study to Compare the Long-term Performance of 4 Designs of the DePuy Ultima LX Stem in Primary Total Hip Replacement Terminated NCT00208351 Phase 3
38 Antioxidant Supplementation in Patients With Kashin-Beck Disease Unknown status NCT00376025 Phase 2
39 TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE Unknown status NCT01791842 Phase 2 Tocilizumab;Placebo
40 A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA Completed NCT00884949 Phase 1, Phase 2 BMN 110
41 Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome) Completed NCT01515956 Phase 2 BMN 110
42 Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial Completed NCT01619644 Phase 2 sodium valproate;Placebo
43 Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome Completed NCT00001728 Phase 2 Fosamax (Alendronate)
44 A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia Completed NCT02055157 Phase 2 BMN 111
45 Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty Completed NCT00001181 Phase 2 Testolactone
46 Do Bisphosphonates Alter the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta? Completed NCT03208582 Phase 2 Risedronate Sodium
47 Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody Denosumab Completed NCT01799798 Phase 2 Denosumab
48 Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta Completed NCT01417091 Phase 2 BPS804
49 Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta Completed NCT00131118 Phase 2 Zoledronic Acid
50 Bisphosphonate Treatment of Osteogenesis Imperfecta Completed NCT00063479 Phase 2 Zoledronic Acid

Search NIH Clinical Center for Mucopolysaccharidosis Iv

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Mucopolysaccharidosis Iv cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Mucopolysaccharidosis Iv:
ALD-151, umbilical cord blood cells for hematologic and immunodefeciency diseases
Embryonic/Adult Cultured Cells Related to Mucopolysaccharidosis Iv:
Umbilical cord blood ALDH+ cells (ALD-151) PMIDs: 10430905

Cochrane evidence based reviews: mucopolysaccharidosis iv

Sources

Genetic Tests for Mucopolysaccharidosis Iv

About this section

Genetic tests related to Mucopolysaccharidosis Iv:

# Genetic test Affiliating Genes
1 Mucopolysaccharidosis, Mps-Iv-a 29 GALNS
Sources

Anatomical Context for Mucopolysaccharidosis Iv

About this section

MalaCards organs/tissues related to Mucopolysaccharidosis Iv:

41
Bone, Heart, Skin, Eye, Brain, Liver, Spinal Cord
Sources

Publications for Mucopolysaccharidosis Iv

About this section

Articles related to Mucopolysaccharidosis Iv:

(show all 17)
# Title Authors Year
1
Evaluation of oral manifestations of patients with mucopolysaccharidosis IV and VI: clinical and imaging study. ( 28315965 )
2017
2
The structure of human GALNS reveals the molecular basis for mucopolysaccharidosis IV A. ( 22940367 )
2012
3
A case of mucopolysaccharidosis IV with lower leg paresis due to thoraco-lumbar kyphoscoliosis. ( 12763346 )
2003
4
Anaesthetic management of patients with mucopolysaccharidosis IV presenting for major orthopaedic surgery. ( 10408824 )
1999
5
Ocular changes in mucopolysaccharidosis IV A (Morquio A syndrome) and long-term results of perforating keratoplasty. ( 10202296 )
1999
6
Mucopolysaccharidosis IV A: molecular cloning of the human N-acetylgalactosamine-6-sulfatase gene (GALNS) and analysis of the 5'-flanking region. ( 8020961 )
1994
7
Mucopolysaccharidosis IV A: assignment of the human N-acetylgalactosamine-6-sulfate sulfatase (GALNS) gene to chromosome 16q24. ( 8325655 )
1993
8
Cataracts in Morquio syndrome (mucopolysaccharidosis IV A). ( 8233358 )
1993
9
Ocular histopathology and ultrastructure of Morquio syndrome (systemic mucopolysaccharidosis IV A). ( 2119328 )
1990
10
Progressive mental regression in siblings with Morquio disease type B (mucopolysaccharidosis IV B). ( 3121219 )
1987
11
Ultrastructure of lymphocytes and skin in mucopolysaccharidosis IV A (Morquio syndrome). ( 6792941 )
1981
12
Morquio syndrome (mucopolysaccharidosis IV B) associated with beta-galactosidase deficiency. Report of two cases. ( 6446239 )
1980
13
Hearing patterns in Morquio's syndrome (mucopolysaccharidosis IV). ( 409383 )
1977
14
The Morquio syndrome (mucopolysaccharidosis IV): Morphologic and biochemical studies. ( 810613 )
1975
15
Oral findings in the Morquio syndrome (mucopolysaccharidosis IV). ( 803669 )
1975
16
Mucopolysaccharidosis IV (MorquiAPs disease) in a twenty-months old child. ( 5004678 )
1971
17
Keratosulfate-chondroitin sulfate peptide from normal urine and from urine of patients with Morquio syndrome (mucopolysaccharidosis IV). ( 4229430 )
1968
Sources

Variations for Mucopolysaccharidosis Iv

About this section

ClinVar genetic disease variations for Mucopolysaccharidosis Iv:

6 (show top 50) (show all 212)
# Gene Variation Type Significance SNP ID Assembly Location
1 GALNS NM_000512.4(GALNS): c.337A> T (p.Ile113Phe) single nucleotide variant Pathogenic rs118204438 GRCh37 Chromosome 16, 88907485: 88907485
2 GALNS NM_000512.4(GALNS): c.337A> T (p.Ile113Phe) single nucleotide variant Pathogenic rs118204438 GRCh38 Chromosome 16, 88841077: 88841077
3 GLB1 NM_000404.3(GLB1): c.601C> T (p.Arg201Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs72555360 GRCh37 Chromosome 3, 33099713: 33099713
4 GLB1 NM_000404.3(GLB1): c.601C> T (p.Arg201Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs72555360 GRCh38 Chromosome 3, 33058221: 33058221
5 GLB1 NM_000404.3(GLB1): c.1233+8T> C single nucleotide variant Benign/Likely benign rs13093698 GRCh37 Chromosome 3, 33063050: 33063050
6 GLB1 NM_000404.3(GLB1): c.1233+8T> C single nucleotide variant Benign/Likely benign rs13093698 GRCh38 Chromosome 3, 33021558: 33021558
7 GLB1 NM_000404.3(GLB1): c.1426C> T (p.Leu476=) single nucleotide variant Uncertain significance rs113534264 GRCh37 Chromosome 3, 33058254: 33058254
8 GLB1 NM_000404.3(GLB1): c.1426C> T (p.Leu476=) single nucleotide variant Uncertain significance rs113534264 GRCh38 Chromosome 3, 33016762: 33016762
9 GLB1 NM_000404.3(GLB1): c.1594A> G (p.Ser532Gly) single nucleotide variant Benign/Likely benign rs73826339 GRCh37 Chromosome 3, 33055688: 33055688
10 GLB1 NM_000404.3(GLB1): c.1594A> G (p.Ser532Gly) single nucleotide variant Benign/Likely benign rs73826339 GRCh38 Chromosome 3, 33014196: 33014196
11 GLB1 NM_000404.3(GLB1): c.1824G> C (p.Leu608=) single nucleotide variant Benign rs77226678 GRCh37 Chromosome 3, 33038747: 33038747
12 GLB1 NM_000404.3(GLB1): c.1824G> C (p.Leu608=) single nucleotide variant Benign rs77226678 GRCh38 Chromosome 3, 32997255: 32997255
13 GLB1 NM_000404.3(GLB1): c.29C> T (p.Pro10Leu) single nucleotide variant Benign rs7637099 GRCh37 Chromosome 3, 33138549: 33138549
14 GLB1 NM_000404.3(GLB1): c.29C> T (p.Pro10Leu) single nucleotide variant Benign rs7637099 GRCh38 Chromosome 3, 33097057: 33097057
15 GLB1 NM_000404.3(GLB1): c.34T> C (p.Leu12=) single nucleotide variant Benign rs7614776 GRCh37 Chromosome 3, 33138544: 33138544
16 GLB1 NM_000404.3(GLB1): c.34T> C (p.Leu12=) single nucleotide variant Benign rs7614776 GRCh38 Chromosome 3, 33097052: 33097052
17 GLB1 NM_000404.3(GLB1): c.458-11T> C single nucleotide variant Benign/Likely benign rs34204221 GRCh37 Chromosome 3, 33107060: 33107060
18 GLB1 NM_000404.3(GLB1): c.458-11T> C single nucleotide variant Benign/Likely benign rs34204221 GRCh38 Chromosome 3, 33065568: 33065568
19 GLB1 NM_000404.3(GLB1): c.792+10G> T single nucleotide variant Benign/Likely benign rs79518579 GRCh37 Chromosome 3, 33094973: 33094973
20 GLB1 NM_000404.3(GLB1): c.792+10G> T single nucleotide variant Benign/Likely benign rs79518579 GRCh38 Chromosome 3, 33053481: 33053481
21 GALNS NM_000512.4(GALNS): c.1177G> T (p.Ala393Ser) single nucleotide variant Benign/Likely benign rs2303269 GRCh37 Chromosome 16, 88891240: 88891240
22 GALNS NM_000512.4(GALNS): c.1177G> T (p.Ala393Ser) single nucleotide variant Benign/Likely benign rs2303269 GRCh38 Chromosome 16, 88824832: 88824832
23 GALNS NM_000512.4(GALNS): c.1413C> T (p.Val471=) single nucleotide variant Benign/Likely benign rs73251084 GRCh37 Chromosome 16, 88884484: 88884484
24 GALNS NM_000512.4(GALNS): c.1413C> T (p.Val471=) single nucleotide variant Benign/Likely benign rs73251084 GRCh38 Chromosome 16, 88818076: 88818076
25 GALNS NM_000512.4(GALNS): c.1431G> A (p.Glu477=) single nucleotide variant Benign rs2303271 GRCh37 Chromosome 16, 88884466: 88884466
26 GALNS NM_000512.4(GALNS): c.1431G> A (p.Glu477=) single nucleotide variant Benign rs2303271 GRCh38 Chromosome 16, 88818058: 88818058
27 GALNS NM_000512.4(GALNS): c.199C> A (p.Leu67Met) single nucleotide variant Benign rs11862754 GRCh37 Chromosome 16, 88909159: 88909159
28 GALNS NM_000512.4(GALNS): c.199C> A (p.Leu67Met) single nucleotide variant Benign rs11862754 GRCh38 Chromosome 16, 88842751: 88842751
29 GALNS NM_000512.4(GALNS): c.510T> C (p.Tyr170=) single nucleotide variant Benign/Likely benign rs3743544 GRCh37 Chromosome 16, 88904086: 88904086
30 GALNS NM_000512.4(GALNS): c.510T> C (p.Tyr170=) single nucleotide variant Benign/Likely benign rs3743544 GRCh38 Chromosome 16, 88837678: 88837678
31 GALNS NM_000512.4(GALNS): c.692C> G (p.Ala231Gly) single nucleotide variant Benign/Likely benign rs34745339 GRCh37 Chromosome 16, 88902199: 88902199
32 GALNS NM_000512.4(GALNS): c.692C> G (p.Ala231Gly) single nucleotide variant Benign/Likely benign rs34745339 GRCh38 Chromosome 16, 88835791: 88835791
33 GALNS NM_000512.4(GALNS): c.708C> T (p.His236=) single nucleotide variant Benign rs1064315 GRCh37 Chromosome 16, 88902183: 88902183
34 GALNS NM_000512.4(GALNS): c.708C> T (p.His236=) single nucleotide variant Benign rs1064315 GRCh38 Chromosome 16, 88835775: 88835775
35 GALNS NM_000512.4(GALNS): c.846C> T (p.Phe282=) single nucleotide variant Benign/Likely benign rs35232749 GRCh37 Chromosome 16, 88901673: 88901673
36 GALNS NM_000512.4(GALNS): c.846C> T (p.Phe282=) single nucleotide variant Benign/Likely benign rs35232749 GRCh38 Chromosome 16, 88835265: 88835265
37 GLB1 NM_000404.3(GLB1): c.325C> T (p.Arg109Trp) single nucleotide variant Benign/Likely benign rs35289681 GRCh37 Chromosome 3, 33110383: 33110383
38 GLB1 NM_000404.3(GLB1): c.325C> T (p.Arg109Trp) single nucleotide variant Benign/Likely benign rs35289681 GRCh38 Chromosome 3, 33068891: 33068891
39 GALNS NM_000512.4(GALNS): c.1462G> A (p.Val488Met) single nucleotide variant Benign/Likely benign rs78127134 GRCh37 Chromosome 16, 88884435: 88884435
40 GALNS NM_000512.4(GALNS): c.1462G> A (p.Val488Met) single nucleotide variant Benign/Likely benign rs78127134 GRCh38 Chromosome 16, 88818027: 88818027
41 GALNS NM_000512.4(GALNS): c.421T> A (p.Trp141Arg) single nucleotide variant Pathogenic/Likely pathogenic rs794727625 GRCh37 Chromosome 16, 88907401: 88907401
42 GALNS NM_000512.4(GALNS): c.421T> A (p.Trp141Arg) single nucleotide variant Pathogenic/Likely pathogenic rs794727625 GRCh38 Chromosome 16, 88840993: 88840993
43 GALNS NM_000512.4(GALNS): c.599C> T (p.Thr200Met) single nucleotide variant Benign/Likely benign rs7187889 GRCh37 Chromosome 16, 88902643: 88902643
44 GALNS NM_000512.4(GALNS): c.599C> T (p.Thr200Met) single nucleotide variant Benign/Likely benign rs7187889 GRCh38 Chromosome 16, 88836235: 88836235
45 GALNS NM_000512.4(GALNS): c.665G> A (p.Arg222Gln) single nucleotide variant Uncertain significance rs140162658 GRCh37 Chromosome 16, 88902226: 88902226
46 GALNS NM_000512.4(GALNS): c.665G> A (p.Arg222Gln) single nucleotide variant Uncertain significance rs140162658 GRCh38 Chromosome 16, 88835818: 88835818
47 APRT; GALNS NM_000512.4(GALNS): c.*36G> A single nucleotide variant Benign rs11076715 GRCh37 Chromosome 16, 88880811: 88880811
48 APRT; GALNS NM_000512.4(GALNS): c.*36G> A single nucleotide variant Benign rs11076715 GRCh38 Chromosome 16, 88814403: 88814403
49 GALNS NM_000512.4(GALNS): c.858G> A (p.Thr286=) single nucleotide variant Conflicting interpretations of pathogenicity rs140299014 GRCh38 Chromosome 16, 88835253: 88835253
50 GALNS NM_000512.4(GALNS): c.858G> A (p.Thr286=) single nucleotide variant Conflicting interpretations of pathogenicity rs140299014 GRCh37 Chromosome 16, 88901661: 88901661
Sources

Expression for Mucopolysaccharidosis Iv

About this section
Search GEO for disease gene expression data for Mucopolysaccharidosis Iv.
Sources

Pathways for Mucopolysaccharidosis Iv

About this section

Pathways related to Mucopolysaccharidosis Iv according to KEGG:

37
# Name Kegg Source Accession
1 Glycosaminoglycan degradation hsa00531
2 Lysosome hsa04142

Pathways related to Mucopolysaccharidosis Iv according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Metabolism 66
Show member pathways
 13.48 APRT ARSH CTSA GALNS GLB1 NEU1
2
Innate Immune System 66
Show member pathways
 13.4 APRT CTSA GALNS GLB1 NEU1
3
Transport to the Golgi and subsequent modification 66
Show member pathways
 12.5 CTSA GLB1 NEU1
4
Synthesis of substrates in N-glycan biosythesis 66
Show member pathways
 11.72 CTSA GLB1 NEU1
5
Sphingolipid metabolism 1 66 37
Show member pathways
 11.66 ARSH CTSA GLB1 NEU1
6
Lysosome 37
11.01 CTSA GALNS GLB1 NEU1
7
Glycosaminoglycan degradation 37
Show member pathways
 10.62 GALNS GLB1
8
Other glycan degradation 37
10.41 GLB1 NEU1
Sources

GO Terms for Mucopolysaccharidosis Iv

About this section

Cellular components related to Mucopolysaccharidosis Iv according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.72 APRT CTSA GALNS GLB1 NEU1
2 extracellular exosome GO:0070062 9.65 APRT CTSA GALNS GLB1 NEU1
3 intracellular membrane-bounded organelle GO:0043231 9.54 CTSA GLB1 NEU1
4 azurophil granule lumen GO:0035578 9.33 CTSA GALNS GLB1
5 lysosome GO:0005764 9.26 CTSA GALNS GLB1 NEU1
6 lysosomal lumen GO:0043202 8.92 CTSA GALNS GLB1 NEU1

Biological processes related to Mucopolysaccharidosis Iv according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratan sulfate catabolic process GO:0042340 9.16 GALNS GLB1
2 glycosphingolipid metabolic process GO:0006687 9.13 CTSA GLB1 NEU1
3 neutrophil degranulation GO:0043312 9.02 APRT CTSA GALNS GLB1 NEU1

Molecular functions related to Mucopolysaccharidosis Iv according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.35 ARSH CTSA GALNS GLB1 NEU1
2 hydrolase activity, acting on glycosyl bonds GO:0016798 9.26 GLB1 NEU1
3 sulfuric ester hydrolase activity GO:0008484 9.16 ARSH GALNS
4 exo-alpha-sialidase activity GO:0004308 8.8 CTSA GLB1 NEU1
Sources

Sources for Mucopolysaccharidosis Iv

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....